Jonathan Rigby Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Jonathan Rigby XERS stock SEC Form 4 insiders trading

Jonathan has made over 5 trades of the Xeris Biopharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Jonathan sold 46,565 units of XERS stock worth $207,680 on 30 August 2018.

The largest trade Jonathan's ever made was selling 88,831 units of Xeris Biopharma Inc stock on 17 August 2018 worth over $413,952. On average, Jonathan trades about 41,504 units every 7 days since 2016. As of 23 August 2018 Jonathan still owns at least 58,599 units of Xeris Biopharma Inc stock.

You can see the complete history of Jonathan Rigby stock trades at the bottom of the page.

What's Jonathan Rigby's mailing address?

Jonathan's mailing address filed with the SEC is C/O XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1810, CHICAGO, IL, 60601.

Insiders trading at Xeris Biopharma Inc

Over the last 6 years, insiders at Xeris Biopharma Inc have traded over $2,845,230 worth of Xeris Biopharma Inc stock and bought 2,912,235 units worth $31,442,123 . The most active insiders traders include Group, Llc Green Jeremy Red..., James E Deerfield Mgmt L.P...., and Garheng Kong. On average, Xeris Biopharma Inc executives and independent directors trade stock every 46 days with the average trade being worth of $197,048. The most recent stock trade was executed by John P. Schmid on 12 August 2024, trading 4,515 units of XERS stock currently worth $10,159.

What does Xeris Biopharma Inc do?

xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.

Xeris Biopharma Inc executives and stock owners

Xeris Biopharma Inc executives and other stock owners filed with the SEC include:

• Paul Edick,
  Chairman of the Board, Chief Executive Officer
• John Shannon,
  President, Chief Operating Officer
• Paul R. Edick,
  Chairman & CEO
• Barry Deutsch,
  Chief Financial Officer
• John P. Shannon,
  Pres, COO & Director
• Beth Hecht,
  Senior Vice President, General Counsel, Corporate Secretary
• Beth P. Hecht J.D.,
  Sr. VP, Gen. Counsel, Corp. Sec. & Director
• John Schmid,
  Lead Independent Director
• BJ Bormann,
  Independent Director
• Marla Persky,
  Independent Director
• Jeffrey Sherman,
  Independent Director
• Dawn Halkuff,
  Independent Director
• Mark Thierer,
  Independent Director
• Kenneth Johnson,
  Senior Vice President, Clinical Development, Regulatory, Quality Assurance and Medical Affairs
• Steven Prestrelski,
  Co-Founder, Chief Scientific Officer
• Dr. Steven J. Prestrelski MBA, Ph.D.,
  Co-Founder & Chief Scientific Officer
• Kevin McCulloch,
  Sr. VP of Global Operations & Bus. Devel.
• Dr. Kenneth E. Johnson Pharm. D., Pharm.D.,
  Sr. VP of Clinical Devel., Regulatory, Quality Assurance & Medical Affairs
• Barry M. Deutsch,
  Exec. Officer
• Allison Wey,
  Sr. VP of Investor Relations & Corp. Communications
• Steven M. Pieper,
  Chief Financial Officer
• Dr. Steven J. Prestrelski,
  Co-Founder & Chief Scientific Officer
• Group, Llc Green Jeremy Red...,
  
• James E Deerfield Mgmt L.P....,
  
• Partners, Ltd.Palmetto Part...,
  
• Barbara Jean Anne Bormann K...,
  Director
• Jonathan Rigby,
  Director
• Kevin Mc Culloch,
  See Remarks
• Steven Pieper,
  See Remarks
• John Johnson,
  Director
• Garheng Kong,
  Director
• Ricki Louise Fairley,
  Director